Undesired Outcomes of the Catania Stent Compared to the Xience Stent in Patients Undergoing Angioplasty: A Double-Blind Randomized Controlled Trial

Document Type : Original Article


1 Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran


Background: The present study tries to compare the unintended outcomes of the Catania stent versus Xience stent in patients undergoing angioplasty. Materials and Methods: In a three month, follow-up, double-blinded, randomized controlled trial, 83 patients undergoing angioplasty, who met the inclusion criteria were entered into the study. After randomization 43 patients were treated with the Xience stent and 40 patients with the Catania stent. Stent-related outcomes such as Cardiac and Non-Cardiovascular Death, Myocardial Infarction (MI), Target Lesion Revascularization (TLR), Stent Thrombosis (ST), Coronary Artery Bypass Grafting (CABG), Peripheral vasculopathy, and Cerebral Vascular Accident (CVA) were compared between the groups. Results: There was no statistically significant difference in the incidence rate of complications and clinical outcomes between the two treatment groups (P > 0.05). The incidence of MI, TLR, CABG operation, peripheral vasculopathy, or CVA was not observed in any patient and there was no statistically difference in mortality (4.7% vs. 2.5%; P = 0.527) and stent thrombosis (2.3% vs. 2.5%; P = 0.735). Conclusion: All in all, the present study could not find the significant differences between the Catania stent and Xience stent in terms of clinical outcomes during the follow-up period.


Htay T, Liu MW. Drug-eluting stent: A review and update. Vasc Health Risk Manag 2005;1:263-76.  Back to cited text no. 1
Kirchner RM, Abbott JD. Update on the everolimus-eluting coronary stent system: Results and implications from the SPIRIT clinical trial program. Vasc Health Risk Manag 2009;5:1089-97.  Back to cited text no. 2
Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.  Back to cited text no. 3
Htay T, Liu MW. Drug-eluting stent: A review and update. Vasc Health Risk Manag 2005;1:263-76.  Back to cited text no. 4
Tamburino C, La Manna A, Di Salvo ME, Sacchetta G, Capodanno D, Mehran R, et al. First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: The ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial. JACC Cardiovasc Interv 2009;2:197-204.  Back to cited text no. 5
Capodanno D, Dipasqua F, Tamburino C. Novel drug-eluting stents in the treatment of de novo coronary lesions. Vasc Health Risk Manag 2011;7:103-18.  Back to cited text no. 6
Waksman R. Late stent thrombosis--the “vulnerable” stent. Catheter Cardiovasc Interv 2007;70:54-6.  Back to cited text no. 7
Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, et al. Impact of Sirolimus-Eluting Stents on Outcome in Diabetic Patients A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) Substudy. Circulation 2004;109:2273-8.  Back to cited text no. 8
Capodanno D, Di Salvo ME, Palmerini T, Sheiban I, Margheri M, Vecchi G, et al. Long-term clinical benefit of drug-eluting stents over bare-metal stents in diabetic patients with de novo left main coronary artery disease: Results from a real-world multicenter registry. Catheter Cardiovasc Interv 2009;73:310-6.  Back to cited text no. 9
Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. JAMA 2005;294:1215-23.  Back to cited text no. 10
Sheiban I, Villata G, Bollati M, Sillano D, Lotrionte M, Biondi-Zoccai G. Next-generation drug-eluting stents in coronary artery disease: Focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag 2008;4:31-8.  Back to cited text no. 11
Onuma Y, Kukreja N, Piazza N, Eindhoven J, Girasis C, Schenkeveld L, et al. The everolimus-eluting stent in real-world patients 6-month follow-up of the X-SEARCH (Xience V) stent evaluated at Rotterdam Cardiac Hospital registry. J Am Coll Cardiol 2009;54:269-76.  Back to cited text no. 12
Park KW, Lee JM, Kang SH, Ahn HS, Yang HM, Lee HY, et al. Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World PracticePatient-Related and Stent-Related Outcomes From the Multicenter Prospective EXCELLENT AND RESOLUTE-Korea Registries. J Am Coll Cardiol 2013;61:536-44.  Back to cited text no. 13
Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, et al. 2-Year Follow-Up of a Randomized Controlled Trial of Everolimus-and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice COMPARE (Comparison of the everolimus eluting Xience-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: A randomized open label trial). J Am Coll Cardiol 2011;58:11-8.  Back to cited text no. 14
Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. EuroIntervention 2006;2:286-94.  Back to cited text no. 15
Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The Spirit first trial. EuroIntervention 2005;1:58-65.  Back to cited text no. 16
Iakovou I. Do the New Data on Second-Generation drug eluting stents provide reassurance on safety, Efficacy, Even for Off-Label Use? Hosp Chron 2010;5:141-4.  Back to cited text no. 17
Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B, et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2007;70:515-23.  Back to cited text no. 18
Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: A meta-analysis. Eur Heart J 2006;27:2784-814.  Back to cited text no. 19
Tamburino C, Capodanno D, Di Salvo ME, Sanfilippo A, Cascone I, Incardona V, et al. Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the Atlanta 2 registry. EuroIntervention 2012;7:1062-8.  Back to cited text no. 20
Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol 2004;4:26.  Back to cited text no. 21
Gupta S, Gupta MM. Stent thrombosis. J Assoc Physicians India 2008;56:969-79.  Back to cited text no. 22
Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004;109:1930-2.  Back to cited text no. 23
Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious? Circulation 2004;109:701-5.  Back to cited text no. 24